Showing posts with label Health. Show all posts
Showing posts with label Health. Show all posts

Wednesday, February 15, 2012

Latest US drug shortage hits children with leukaemia

Stocks of a vital cancer drug are running low in the US, which could affect children with leukaemia within weeks.
The US Food and Drug Administration says a number of drug manufacturers are flagging up shortages in methotrexate – which slows the growth of white blood cells in acute lymphoblastic leukaemia, a cancer that typically affects young children.
Manufacturing delays and unexpectedly high levels of demand are blamed for the shortfall, together with the voluntary closure of Ben Venue Laboratories, one of the nation's largest suppliers of the drug.
Oncologists are concerned supplies could run out in some areas within weeks. Reports suggest that the FDA is seeking a foreign supplier to provide emergency imports until domestic ones can meet demand.
Legislation designed to give an early warning of drug shortages was passed to a government committee last summer.

http://www.newscientist.com/
»»  Read More...

Tuesday, February 14, 2012

Quantum dots control brain cells for the first time

 Nerve cells like these could be controlled by quantum dots <i>(Image: CNRI/Science Photo Library)</i>
Nerve cells like these could be controlled by quantum dots (Image: CNRI/Science Photo Library)

In an unlikely marriage of quantum physics and neuroscience, tiny particles called quantum dots have been used to control brain cells for the first time.
Having such control over the brain could one day provide a non-invasive treatment for conditions such as Alzheimer's disease, depression and epilepsy. In the nearer term, quantum dots could be used to treat blindness by reactivating damaged retinal cells.
"Many brain disorders are caused by imbalanced neural activity," says Lih Lin at the University of Washington, Seattle. "Manipulation of specific neurons could permit the restoration of normal activity levels."
Methods to stimulate the brain artificially already exist, though each has its drawbacks. Deep brain stimulation is used in Parkinson's disease to trigger brain cell activity and prevent the abnormal signalling that causes debilitating tremors, but placing the electrodes required is highly invasive. Transcranial magnetic stimulation can stimulate brain cells from
outside the head, but is not highly targeted and so affects large areas of the brain at once. Researchers in optogenetics can control genetically modified brain cells using light but because of these modifications, the technique is not yet deemed safe to use in humans.
Lin's team has now come up with an alternative using quantum dots – light-sensitive, semiconducting particles just a few nanometres in diameter.
First, they cultivated prostate cancer cells on a film covered with quantum dots. The cell membranes of the cancer cells were positioned next to the dots. The team then shone light onto the nanoparticles.
Energy from the light excites electrons within the quantum dot which causes the surrounding area to become negatively charged (see diagram). This caused some of the cancer cells' ion channels, which are mediated by a voltage, to open, allowing ions to rush in or out of the cells.
In nerve cells, opening ion channels is a crucial step in generating action potentials – the signals by which the cells communicate in the brain. If the voltage change is large enough, an action potential is generated.
When Lin's team repeated their experiment with nerve cells, they found that stimulating the quantum dots caused ion channels to open and the nerve cell to fire.
In humans, quantum dots would need to be delivered to brain tissue. Lin claims this shouldn't be a problem. "A significant advantage is that their surface can be modified with various molecules," she says. These molecules could be attached to the quantum dots in order to target specific brain cells and could be administered intravenously.
A key hurdle would be delivering the light source to the brain. For this reason, Lin reckons the first use for the technique would be in reactivating damaged cells in the retina, which naturally absorb light. Co-author Fred Reike, who specialises in retinal disease, says that quantum dots have great potential in this area because they directly affect ion channels, which play a key part in the signalling pathways of vision.
"Quantum dots have a great future for biomedical applications," agrees Kevin Critchley at the University of Leeds, UK, but adds that there are limitations such as potential toxicity issues.
"Based on what we have observed, we are optimistic about the potential of this technology in helping us [answer] biological questions, and eventually diagnose and treat human diseases," Lin says.
Journal reference: Biomedical Optics Express, DOI: 10.1364/boe.3.000447

http://www.newscientist.com/
»»  Read More...

Dark side of the love hormone


The "cuddle chemical" oxytocin bonds mothers to their babies and sniffing it makes adults nicer – but can also foster gloating and racism

FEW chemicals have as glowing a reputation as oxytocin. Billed as the "love hormone" or the "cuddle chemical", it has been linked to almost every positive aspect of the human psyche. One whiff of it can make a person more trusting, empathetic, generous and cooperative. Such is its popular appeal that you can even buy it as a spray from dubious internet dealers.
It is time to revise this rose-tinted view. A new wave of studies is showing that oxytocin is neither the cause of our better angels nor a panacea for the world's social ills. In fact, its effects vary greatly depending on the person and the circumstances, and it can tweak our social interactions for worse as well as for better. The "love hormone", it turns out, has a dark side, one that is only just starting to come to light. "It isn't the wonder drug that makes everyone happy and social," says Markus Heinrichs at the University of Freiburg, Germany, who pioneered work on oxytocin.
We first became aware of the hormone's social influence through animal studies. It helps to cement the bonds between prairie voles, which mate for life, and triggers the motherly behaviour that sheep show towards their newborn lambs. It is also released in humans during childbirth, strengthening the attachment between mother and baby.
Its wider role in human behaviour only emerged in 2005 when, in a groundbreaking experiment, Heinrichs and colleagues asked volunteers to play a game in which they could invest money with an anonymous trustee, who was not guaranteed to be honest. The team found that participants who had sniffed oxytocin via a nasal spray beforehand invested more money than those given a placebo (Nature, vol 435, p 673).
The study kick-started research into the effects of oxytocin on human behaviour. "For eight years, it was quite a lonesome field," Heinrichs recalls. "Now, everyone is interested." Many of the follow-up studies came from the same mould as the original experiment, involving groups of volunteers being given either oxytocin or a placebo and then carrying out a task to test their social skills. Such studies have shown that after a sniff of the hormone, people donate more money to charity, become better at reading emotions on other people's faces, communicate more constructively during arguments, and perceive others to be more trustworthy, attractive and approachable. Together, the results fuelled the view that oxytocin universally enhances the positive aspects of our social nature.
Then, a couple of years ago, contrasting findings began to emerge. Simone Shamay-Tsoory at the University of Haifa, Israel, showed that as well as promoting trust and generosity, oxytocin can heighten feelings of envy and schadenfreude (Journal of Biological Psychiatry, vol 66, p 864). When volunteers played a gambling game, those who inhaled the hormone gloated more when they beat other players. They also felt sharper stabs of jealousy when the tables were turned. Clearly, oxytocin can produce antisocial as well as social behaviour.


A new wave of studies is showing that oxytocin is neither the cause of our better angels nor a panacea for the world's social ills <i>(Image: Phil Ball/Rex Features)</i>
A new wave of studies is showing that oxytocin is neither the cause of our better angels nor a panacea for the world's social ills (Image: Phil Ball/Rex Features)
That's not all. The hormone also has sharply contrasting effects depending on a person's disposition. Jennifer Bartz from the Mount Sinai School of Medicine, New York, found that it improves people's ability to read emotions, but only if they are not very socially adept to begin with (Psychological Science, vol 21, p 1426). Her team also showed that oxytocin actually reduces trust and cooperation in people who are particularly anxious or sensitive to rejection (Social Cognitive and Affective Neuroscience, vol 6, p 556). It can even alter our memories in different ways. It gives people fonder recollections of their mothers, but only if they are secure in their personal relationships. If they are socially anxious, oxytocin makes them remember their mums as being less caring and more distant (Proceedings of the National Academy of Sciences, vol 107, p 21371).
The effects of oxytocin can also depend on a person's culture. Although we have yet to fully unravel the complex biochemical pathways by which this hormone shapes behaviour, we do know that it starts off by docking onto a protein found throughout the nervous and reproductive systems, one encoded by the OXTR gene. A change in one of the gene's DNA letters, from A to G, makes people more socially sensitive. G-carriers tend to be more empathetic and less lonely. They are also more likely to turn to their friends in times of trouble, but only if they live in a culture where it is customary to seek companionship when distressed. Heejung Kim of the University of California, Santa Barbara, found that in South Korea - where it is often a faux pas to burden friends with your problems - G-carriers are no more likely, and may in fact be slightly less likely, to seek solace from their social circles than A-carriers (Proceedings of the National Academy of Sciences, vol 107, p 15717). So a single trait, social sensitivity, plays out in radically different ways against the backdrops of different cultures.

Another discovery is that oxytocin's effects vary depending on who we interact with. Carolyn DeClerck of the University of Antwerp, Belgium, found that people under the hormone's influence become more cooperative only if they have some information about their partner. When paired with anonymous strangers, they become less cooperative. Meanwhile, Carsten de Dreu at the University of Amsterdam in the Netherlands discovered that oxytocin-sniffers show more trust and cooperation towards their compatriots, but not people of other nationalities (Science, vol 328, p 1408). They also showed favouritism: Dutch men became quicker to associate positive words with Dutch names than with German or Arabic ones, for example. De Dreu says that oxytocin promotes a "tend and defend" response, one that drives people to care for those in their social circles and protect them from outside dangers. "It's what we call the mama-bear effect," he says. So, rather than promoting blanket goodwill, oxytocin strengthens biases.
There were signs of these subtleties from the start. Bartz has recently shown that in almost half the existing studies, oxytocin held sway only over certain individuals or in particular circumstances (Trends in Cognitive Sciences, vol 15, p 301). Where once researchers ignored such findings, now a more nuanced understanding of oxytocin's effects is propelling investigations down new lines.
To Bartz, the key to understanding what the hormone does lies in pinpointing its core function rather than in cataloguing its seemingly endless effects. There are several hypotheses, which are not necessarily mutually exclusive. Oxytocin could help to reduce anxiety and fear. Or it could simply motivate people to seek out social connections, which would account for a rise in trust and cooperation, but also explain why oxytocin-sniffers gravitate towards others resembling themselves, and why people who fear social rejection are not necessarily better off with more of the hormone.
For her part, Bartz favours the social salience hypothesis. The idea here is that oxytocin acts as a chemical spotlight that shines on social cues - a shift in posture, a flicker of the eyes, a dip in the voice - making people more attuned to their social environment. This would explain why it makes us more likely to look others in the eye and improves our ability to identify emotions. For people with autism who are less able to pick up on social cues, oxytocin could bring those subtle signs into sharp focus (see "Treat with care"). But it could make things worse for people who are overly sensitive and prone to interpreting social cues in the worst light. "People may become more empathic or protective, but they may also become more vigilant or competitive," says De Dreu. "It depends on who they are and the other people that they're dealing with."
Perhaps we should not be surprised that the oxytocin story has got more complicated. The hormone is found in everything from octopuses to sheep, and its evolutionary roots stretch back half a billion years. "It's a very simple and ancient molecule that has been co-opted for many different functions, from lactation to social behaviour," says Sue Carter at the University of Illinois, Chicago, who did many of the early studies in animals. "It affects primitive parts of the brain like the amygdala, so it's going to have many effects on just about everything." Bartz agrees. "Oxytocin probably does some very basic things, but once you add our higher-order thinking and complex behaviours and social situations, these basic processes could manifest in different ways depending on individual differences and context."

Treat with care

With around 40 clinical trials under way using oxytocin to treat conditions such as autism and schizophrenia, there is a lot of optimism that the hormone could help people by boosting trust and reducing social anxiety. However, there is also a growing realisation that under certain circumstances oxytocin can make people more antisocial (see main story). Understanding these subtle effects could mean the difference between helping someone and making things worse.
"From the early data, it's very clear that oxytocin alone will do nothing," says Markus Heinrichs at the University of Freiburg, Germany. "If you sit at home with a social phobia and someone prescribes a nasal oxytocin spray, I bet that the only effect you'd get would be a dripping nose." The trick is to work out when and in whom oxytocin would be expected to improve social behaviour, undermine it, or do nothing. For example, people might respond differently depending on how much of the hormone naturally courses through their blood, their emotional state at the time of inhalation, or which version of a gene called OXTR they have. Combining treatment with counselling should help get the best results, provided people identify with their therapist and so are likely to experience the positive side of oxytocin's effects.
Researchers are addressing these issues, but meanwhile oxytocin sprays are readily available online. "We know people are buying it off the internet and trying to use it to treat children with autism," says Sue Carter at the University of Illinois, Chicago. In most cases, the amount of hormone in the sprays is so low that they cannot be effective. Still, Carter points out that no one knows the long-term consequences of inhaling oxytocin, or what happens when you give it to young children. "This is very worrying," she says.
Ed Yong is a science writer based in London

http://www.newscientist.com/
»»  Read More...

Why full disclosure is healthy

<i>(Image: Andrzej Krauze)</i>
(Image: Andrzej Krauze)

Do British people know enough about the financial interests of those writing health articles? Time to toughen editorial codes

LAST year, the BBC News website published an article that questioned if psychological therapies were enough to tackle the rise of depression in the UK. "Is it time," asked the author, "to question our seeming obsession with talking treatments? I want to stand up for the very important role medication can play in the treatment of mental illness."
What stood out for me was not just the pro-pill stance, but an endnote that its author, Richard Gray, a professor in nursing research at the University of East Anglia, Norwich, had "given lectures on behalf of a number of pharmaceutical companies". It did not state he had been paid for them, or that he had received fees and honoraria from antidepressant manufacturers, including AstraZeneca and Eli Lilly, for consultancy work.
This kind of omission happens all the time, so why single out this case? Primarily because the site is run by the BBC, a global media corporation. And the thousands reading the article could not judge its impartiality because they did not know about the payments.
After trying to get a comment for some time, the BBC agreed to amend the endnote. But at medical journals such as The Lancet failure to disclose payments would have breached editorial codes. In the UK, we rely on codes, in the US, media outlets are legally obliged to declare potential vested interests.
Sophie Corlett of Mind, a UK mental health charity, thinks we should take this seriously. "People experiencing mental health problems look to professionals... for many, this includes information that filters through the media. The responsibility to inform readers of issues which may affect the impartiality of a published piece lies with... news outlets and contributing authors. Mind has long campaigned for medical information to be conveyed in an open and balanced manner... we encourage... disclosure of interests."
This is happening at a time when concern is mounting over industry influence on psychiatric research and practice, and on public opinion. Trials of antidepressants are mostly funded, and often analysed and directed, by pharmaceutical companies. Some 60 per cent of the task force behind DSM-IV (the psychiatrists' diagnostics handbook) received money from pharma, as have most research centres and many heads of psychiatry schools. Of the 29 experts writing DSM-5, 21 received honoraria, consultancy fees or funding from pharma.
The BBC defends its coverage: "It's common for the BBC to speak to people with expertise in a particular subject. We do so under clear editorial guidelines that contributors associated with a particular viewpoint or with a commercial interest in a subject should be clearly signposted... Nothing has been put to us which suggests that there has been any conflict of interest."
So the BBC aims to ensure articles are signposted. In this case one slipped through the net and was duly amended. But it must be more alert to contentious topics and conflicts of interest. Perhaps its code needs tightening - or we should consider a law.
James Davies is a senior lecturer in social anthropology and psychotherapy at the University of Roehampton, London

http://www.newscientist.com/
»»  Read More...

Monday, February 13, 2012

Child abuse shrinks key brain memory centre

 Maltreatment of children may stunt growth of the hippocampus, a brain region vital for memory. That's the conclusion of a study of 193 outwardly healthy adults aged 18 to 25 from the Boston area.
The stunted hippocampi could help explain how childhood stress raises the risk of psychiatric disorders in adulthood, ranging from depression, schizophrenia and post-traumatic stress disorder to personality disorders, drug addiction and even suicide.
Martin Teicher of McLean Hospital in Belmont, Massachusetts, and colleagues used standard questionnaires to reveal which volunteers had suffered abuse as children, and found size differences in regions of the hippocampus through detailed MRI brain scans.
Big differences were seen in people who said that as children they had experienced verbal, physical or sexual abuse, physical or emotional neglect, bereavement, parental separation or parental discord. Three sub-regions of the hippocampus were between 5.8 and 6.5 per cent smaller in such volunteers, compared with those who reported no maltreatment.

Stress strike

The three sub-regions – the dentate gyrus, the cornu ammonis and the subiculum – are all known to be vulnerable to the effects of stress hormones, which probably interfere with the formation of cells and new tissue as the immature brain develops.
"These findings support the hypothesis that exposure to early stress in humans, as in other animals, affects hippocampal development," concludes Teicher's team. They say that the study is the largest and most detailed yet to examine the phenomenon in people, and the results echo those seen in the hippocampi of rats and monkeys subjected to stress as infants.
Child abuse or poverty can also alter which genes are active in the developing brain through a process called epigenesis. These changes can lead to diseases such as schizophrenia and bipolar disorder.
"Childhood maltreatment is like a surgical strike on the brain," says Carmine Pariante, who studies the effects of stress on child development at the Institute of Psychiatry, Kings College London. "This explains why these individuals are at risk of developing a host of stress-related disorders later in life – because they have an impaired ability to cope with stress."
"Findings like this indicate that maltreatment can leave damage hidden deep inside the body that persists for many years," says Terrie Moffitt of Duke University in Durham, North Carolina. "Once we appreciate that child maltreatment brings hidden damage that can resurface years later as memory problems, preventing child abuse seems like a very good deal."
Journal reference: Proceedings of the National Academy of Sciences, DOI: 10.1073/pnas.1115396109

http://www.newscientist.com/
»»  Read More...

Ancient Chinese medicine could fight ageing

A flowering Tibetan shrub that tricks cells into thinking they are starving could become a weapon against multiple sclerosis and even old age.
The roots of the blue evergreen hydrangea (Dichroa febrifuga) have been used for centuries in traditional Chinese medicine to treat malaria. Now Tracy Keller and colleagues at the Harvard School of Dental Medicine in Boston have found that halofuginone – a chemical based on the roots' active ingredient – blocks immune reactions that can cause disease.
Cells stop the synthesis of non-vital proteins when amino acids are in short supply. Keller's team discovered that halofuginone mimics such a shortage by blocking an enzyme that feeds one amino acid to the protein-making machinery.
Keller found that the drug triggers a chemical cascade that responds to amino acid scarcity, called AAR. This inhibits the growth of malaria parasites, stops blood cells from making proteins that cause inflammation, and stops the development of specific white blood cells that trigger conditions such as inflammatory bowel disease and multiple sclerosis.
This could make the drug effective against autoimmune disease. But as halofuginone mimics nutrient deprivation, there is another possible use. Animals that receive only just adequate nutrition are known to live longer, partly because diseases which involve inflammation are prevented. That, says Keller, means halofuginone might possibly work as an anti-ageing drug.

Journal reference: Nature Chemical Biology, DOI: 10.1038/nchembio.790

http://www.newscientist.com/
»»  Read More...

Friday, February 10, 2012

New surgery heals nerve damage in weeks

 You've got a lot of nerve <i>(Image: Science Picture Co/Science Faction/Corbis Left:SPL/Corbis)</i>
You've got a lot of nerve (Image: Science Picture Co/Science Faction/Corbis Left:SPL/Corbis)

THE once paralysed limb began to twitch just minutes after the operation. It was an early sign that the rat was on a fast track to recovery that would see it up and running within weeks.
The rodent is one of more than 200 to have undergone a new surgical procedure for nerve repair that provides faster - and better - results in animals than existing techniques. The crucial question is: can it work as well in humans with the sorts of injuries that the real world inflicts upon us?
"In animal models, the results are better than any current techniques used for nerve repair," says Wesley Thayer of Vanderbilt University in Nashville, Tennessee, a member of the team behind the new procedure.
So far, Thayer and team leader George Bittner of the University of Texas at Austin have used the new technique to treat rats after severing their sciatic nerve, which mediates leg movement and feeling. With plans afoot to begin clinical trials and work also under way to see if the procedure can heal spinal cord injuries in rats, nerve specialists are cautiously optimistic that Bittner and Thayer are on to something.
When a nerve is severed through injury, surgeons must suture the two stumps together as quickly as possible. Yet even under controlled lab conditions, Bittner's tests in rats suggest that these conventional sutures restore little more than 30 per cent of previous mobility, even three months after surgery. His new technique helps to restore twice that, in as little as two weeks. The secret, he says, is to prevent the body lending a helping hand.
Put bluntly, the body botches nerve repair. It forms seals over the two severed stumps of a broken nerve within an hour, says Bittner, but it doesn't reconnect them first. Even if surgeons then suture the two ends, the seals will prevent nerve signals from passing easily across the join (see "Bound together").
Bittner realised that we need a system that blocks the body's repair process. The way to do that, he discovered, is to immediately flush the injury site with a calcium-free salty solution that also contains methylene blue, a chemical that blocks oxidation reactions. Calcium and oxidation drive the formation of tiny spheres called vesicles, which in turn seal the nerve stumps.
The two still-unsealed stumps can then be glued together using polyethylene glycol, or PEG, which Bittner says allows the outer insulating layers of the nerve to join up more efficiently than they would through suturing.
Only when the nerve has been glued together does Bittner restart the body's natural local repair mechanism - by injecting a calcium-rich salty solution. Vesicles quickly consolidate the join (Journal of Neuroscience Research, DOI: 10.1002/jnr.23022 and 10.1002/jnr.23023).
All the substances for the procedure are already in medical use. "We are planning a small clinical trial once we have more safety data," says Thayer.
Work is also under way to see if the technique could help heal the spinal cord as well as the nerves that branch from it. Bittner says he's already shown that the new procedure works on spinal cords "in a dish", and evaluations in animals have been done too, but he is keeping these results under wraps until the work is published in a peer-reviewed journal.
Other nerve specialists are fascinated by the results, but all warn that the outcome might not be as impressive in injured humans because real-world wounds are often much more complex than those produced in the lab rats. "Clinical injuries are normally messy, not carefully controlled microlesions," says John Priestley of Queen Mary, University of London.
Giorgio Terenghi at the University of Manchester, UK, says that the technique won't work in people with injuries that are more than a few days old. Not only will the nerve stumps have sealed, but the chunk of nerve cut adrift from the rest of the nervous system begins to decay. Bittner and Thayer say they are working on ways to improve the survival time of the isolated section.
The caution greeting the new work is understandable, given that researchers are keen to avoid raising hopes prematurely. But it was also mixed with optimism. "As a beginning it's very encouraging," says Terenghi.
"It would be a major breakthrough if the severed pieces of a nerve could be just glued together - although most research indicates that this is not possible," says Priestley. "The two new papers describe something truly startling and exciting."

http://www.newscientist.com/
»»  Read More...

Cancer drug reverses Alzheimer's in mice

What a quick turnaround: a drug used to treat cancer can reverse Alzheimer's disease in mice – and it takes just 72 hours to work its magic. It remains to be seen if the drug has the same effect in people with Alzheimer's, though.
Alzheimer's disease is associated with deposits of beta-amyloid peptides in the brain. The build-up is thought to underlie the abnormal brain activity that leads to memory problems, and also kick-starts a chemical cascade that ultimately leads to the death of neurons.
Paige Cramer at Case Western Reserve University School of Medicine in Cleveland, Ohio, reckoned it might be possible to prevent that build-up using bexarotene, an anti-cancer drug. She reasoned that a healthy brain can clear beta-amyloid deposits through a process facilitated by a substance called apolipoprotein E (ApoE). ApoE is activated in part by a receptor called RXR – and bexarotene enhances the action of RXR.
When mice with Alzheimer's-like brain damage were given bexarotene orally, they were able to clear more than half of the beta-amyloid peptides from the brain within 72 hours. They also showed a rapid reversal of cognitive and social deficits.
Cramer says she hopes to begin phase 1 clinical trials in the next few months. "We believe that because bexarotene is approved [for use in humans], we will be able to transition much more quickly from basic research to the clinic," she says.

Caution needed

Other researchers caution that the study, while encouraging, does not mean that the drug will work so well in people with Alzheimer's. Many drugs that have shown promising results in mice fail to have similar effects in humans.
"The drug development world is littered with drugs that seemed to work on transgenic mice, but didn't work on people," says Derek Hill at University College London. "A programme of clinical trials is needed to assess whether these potentially promising results translate into an effect on the human disease."
David Allsop, a neuroscientist at the University of Lancaster, UK, agrees. "It looks promising in the mouse model, but in recent years these types of experiments in mice have not translated well into humans, and so it is too early to get excited about the prospect of an effective therapy for Alzheimer's disease," he says

Journal reference: Science, DOI: 10.1126/science.1217697

http://www.newscientist.com/
»»  Read More...